- Scientists have developed a new type of CAR T cell therapy that could be more effective in treating multiple myeloma, a type of blood cancer.
- This new therapy uses fifth-generation CAR T cells that target a protein called BCMA found on myeloma cells.
- The researchers found that their fifth-generation anti-BCMA CAR T cells were better at killing myeloma cells and had a higher proliferative capacity than previous generations of CAR T cells.
- The fifth-generation CAR T cells were also better at overcoming a mechanism used by cancer cells to evade the immune system.
- This new therapy could lead to better outcomes for patients with multiple myeloma.
เงินทุน
- มหาวิทยาลัยมหิดล
- National Science and Technology Development Agency (NSTDA)
- Siriraj Research Fund
- Office of National Higher Education Science Research and Innovation Policy Council (NXPO)
- สำนักงานคณะกรรมการวิจัยแห่งชาติ (วช.)
กระดาษต้นฉบับ
ชื่อบทความต้นฉบับ: Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma
วารสาร: Biomedicine & Pharmacotherapy
ดอย: https://doi.org/10.1016/j.biopha.2023.115691